Jefferies Financial Group Inc. Takes $1.88 Million Position in BeOne Medicines Ltd. – Sponsored ADR $ONC

Jefferies Financial Group Inc. purchased a new stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 6,200 shares of the company’s stock, valued at approximately $1,884,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Capital International Investors raised its position in shares of BeOne Medicines by 3.3% during the 3rd quarter. Capital International Investors now owns 5,046,058 shares of the company’s stock valued at $1,716,883,000 after buying an additional 161,052 shares in the last quarter. Bank of America Corp DE raised its position in shares of BeOne Medicines by 23.5% during the 3rd quarter. Bank of America Corp DE now owns 345,256 shares of the company’s stock valued at $117,629,000 after buying an additional 65,763 shares in the last quarter. Man Group plc purchased a new stake in shares of BeOne Medicines during the 2nd quarter valued at $59,031,000. BNP Paribas Financial Markets purchased a new stake in shares of BeOne Medicines during the 2nd quarter valued at $38,337,000. Finally, UBS Group AG raised its position in shares of BeOne Medicines by 45.0% during the 4th quarter. UBS Group AG now owns 152,087 shares of the company’s stock valued at $46,206,000 after buying an additional 47,172 shares in the last quarter. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeOne Medicines Trading Down 0.8%

NASDAQ ONC opened at $300.01 on Thursday. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $235.57 and a 1-year high of $385.22. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The stock has a 50-day moving average of $301.85 and a 200-day moving average of $321.12. The firm has a market cap of $32.92 billion, a PE ratio of 67.12 and a beta of 0.50.

BeOne Medicines (NASDAQ:ONC) last released its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The company had revenue of $1.51 billion during the quarter. As a group, sell-side analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 5.65 EPS for the current year.

Insider Buying and Selling

In related news, Director Margaret Dugan sold 212 shares of BeOne Medicines stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $309.60, for a total value of $65,635.20. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Corazon (Corsee) D. Sanders sold 212 shares of BeOne Medicines stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $309.59, for a total transaction of $65,633.08. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 1,641 shares of company stock worth $505,791. Insiders own 6.19% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on ONC shares. Leerink Partners increased their price objective on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a research report on Friday, May 15th. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Barclays increased their price objective on BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Finally, Guggenheim increased their price objective on BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $389.15.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.